



IMCB-Miltenyi Biotec Joint Symposium 2019

# Advances in immuno-oncology: Engaging new mechanisms for next generation cancer care

Thursday, July 4, 2019

09:30 a.m.–03:30 p.m.

Biopolis Matrix Level 4, Exploration Theatre, Singapore

## PROGRAM

<p><b>Chair:</b></p> <p><b>09:20 a.m.</b></p> <p><b>09:50 a.m.</b></p> <p><b>10:00 a.m.</b></p> <p><b>10:30 a.m.</b></p> <p><b>11:00 a.m.</b></p> <p><b>11:30 a.m.</b></p>	<p><b>John Connolly, Ph.D.</b> Senior Principal Investigator and Director for Translational Immunology Institute of Molecular and Cell Biology, A*STAR, Singapore</p> <p><b>Breakfast and registration</b></p> <p><b>Opening and welcome by John Connolly</b></p> <p><b>Cytokine communication in inflammation and cancer: the T cell–phagocyte interface</b> Burkhard Becher, Ph.D. Chairman, Institute of Experimental Immunology University of Zurich, Switzerland</p> <p><b>Personalized TCR T cell therapy for HBV-related hepatocellular carcinoma</b> Anthony Tanota Tan, Ph.D. Senior Research Fellow Duke-NUS Medical School, Singapore</p> <p><b>Chimeric Antigen Receptor (CAR) T cells targeting TIM-3 to treat acute myeloid leukemia</b> Wang Cheng-I Principal Investigator Singapore Immunology Network, Singapore</p> <p><b>Lights, microscope, and action</b> Ng Lai Guan, Ph.D. Principle Investigator Singapore Immunology Network, Singapore</p>	<p><b>12:00 p.m.</b></p> <p><b>01:30 p.m.</b></p> <p><b>02:00 p.m.</b></p> <p><b>02:30 p.m.</b></p> <p><b>03:00 p.m.</b></p> <p><b>03:30 p.m.</b></p>	<p><b>Lunch and network</b></p> <p><b>Chimeric antigen receptor (CAR) T cell therapy: an overview and update</b> Soh Shui Yen, MBBS, MRCPCH (UK) Head and Senior Consultant, Pediatric Hematology / Oncology Service KK Women’s and Children’s Hospital, SingHealth, Singapore</p> <p><b>Clinical results of a first-in-human phase 1 study of point of care manufactured bispecific anti-CD19, anti-CD20 chimerism antigen receptor modified (LV20.19CAR) T cells for relapsed, refractory, non-Hodgkin lymphoma</b> Nirav Shah, M.D., MSHP Medical College of Wisconsin, Milwaukee, WI, USA</p> <p><b>TBA</b> John Connolly, Ph.D. Senior Principal Investigator and Director for Translational Immunology Institute of Molecular and Cell Biology, A*STAR, Singapore</p> <p><b>Panel discussion</b></p> <p><b>Closing remarks</b></p>
--	---	---	--

► [miltenyibiotec.com](http://miltenyibiotec.com)

Miltenyi Biotec provides products and services worldwide. Visit [www.miltenyibiotec.com/local](http://www.miltenyibiotec.com/local) to find your nearest Miltenyi Biotec contact.

Unless otherwise specifically indicated, Miltenyi Biotec products and services are for research use only and not for therapeutic or diagnostic use. The statements and other contributions presented at the meeting and the views expressed therein are those of the attending experts and do not necessarily represent the policy or opinion of Miltenyi Biotec or any institution the respective expert may be associated with. Neither Miltenyi Biotec nor any of its directors or employees give any representation or warranty as to the reliability, accuracy, or completeness of the content thereof. Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities. This notice must accompany any further distribution of this document. MACS and the MACS logo are registered trademarks or trademarks of Miltenyi Biotec GmbH and/or its affiliates in various countries worldwide. Copyright © 2019 Miltenyi Biotec GmbH and/or its affiliates. All rights reserved.